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Over the last decade, it has become evident that homologous transfusions carry immunologic
consequences beyond the well-understood ones of alloimmunization to blood cell antigens.
Transfusions constitute temporary transplants of large amounts of allogeneic antigen given
intravenously and causedown-regulation ofmanycellular immune functions. Thesechanges may
explain in part theassociation oftransfusion with suchclinically importantevents as (1) improved
survival ofrenal allografts, (2) decreased recurrence rates for autoimmune disease, (3) increased
frequency and earlier recurrences of solid tumors, (4) increased frequency of post-operative
bacterial infection, and (5) increased severity ofviral infection. Preliminary data suggest that, in
animal models and clinical settings, syngeneic or autologous transfusions are not associated with
such events. This finding supports the hypothesis that these associations are cause and effect and
involve immunologic mechanisms.
INTRODUCTION
For some years it has been known that transfusion has generalized immunologic
effects on recipients in addition to the well-known clinically significant effect of
alloimmunization to various blood cell or plasma antigens [1]. The best characterized
clinical effect due to transfusion-induced immunomodulation is improved survival of
renal allografts in previously transfused patients [2]. The mechanism of this effect is
still largely mysterious but is almost universally considered to involve down-regulation
of the immune functions that lead to rejection ofhistoincompatible tissue [3]. During
the 1980s extensive clinical investigation, largely phenomenologic, has yielded evi-
dence that these transfusion-induced effects may not be restricted to the allograft
setting. It has been hypothesized that transfusion may compromise host defenses
against solid tumors [2-6], bacterial organisms [6,7], and viruses [8]. Most recently,
transfusion has been implicated as favorably modifying the course of Crohn's disease
(regional enteritis), a gastrointestinal disease of possible autoimmune etiology [9,10].
Transfusion in the clinical setting is implicated as a potential suppressor of immuno-
logic effector cells and as a stimulator ofimmunologic suppressor cells. We will briefly
review the evidence for these contentions, except for the renal allograft effect, which
will be addressed by one ofthe other symposium participants.
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TRANSFUSION AND IMMUNE FUNCTION
We have recently reviewed this subject elsewhere [1]. Transfusion in both animal
models and clinical settings appears to increase the generation of host suppressive
activity in the form ofsuppressor cells and anti-idiotypicantibodies. This result is most
strikingly seen when the suppression is measured as donor-specific, after initial
exposure to large amounts ofdonor antigen intravenously. Subsequentchallengewith a
donor allograft is frequently followed by extended survival ofhistoincompatible tissue
as compared with its survival in animals or patients not previously exposed to donor
blood. There also appear to be generalized, but poorly characterized decreases in
recipient functions such as cytotoxic or natural killer cells, monocyte/macrophage
migration to sites of infection, ability to respond to mitogens or skin test antigens, and
so on. The components of transfused blood responsible for these effects, which have
been frequently although not universallyobserved, areuncertain. Based upon the renal
allograft setting, white blood cells are thought to be major contributors, but, in some
animal model systems, plasma or red cells have been observed to cause qualitatively
similar effects. In general, many studies ofthis sort would benefit from repetition using
more highly purified blood components and more modern, sophisticated tests of
immune function.
TRANSFUSION AND CANCER RECURRENCE
Perhaps the most controversial question is whether homologous transfusion is
associated with earlier or increased numbers of recurrences of solid tumors [2-6].
While almost all studies demonstrate that transfused patients fare poorly in terms of
time to or frequency of recurrence compared with non-transfused patients, these
differences have not always reached statistical significance. In some instances, the
difference in outcome between transfused and non-transfused patients has been
significant and large, but multivariate analysis determined that, after variables such as
tumor stage, complexityofsurgery, and the like were accounted for, transfusion was no
longer a statistically significant independent predictor of recurrence.
A number offactors probably contribute to thevariability ofresults reported in such
studies. First, all studies to date have been retrospective reviews of previously treated
patients. This method inevitably involves loss to follow-up of many patients and
variations in treatment practices over time in any given single institution. Second,
transfusion is not a random variable. Transfused patients tend to be those who are
having the longest operations and lowest hematocrits prior to surgery. Third, other
variables may contribute to the degree of post-transfusion immunomodulation. Some
anesthetic agents may beimmunosuppressive, and variation in anesthesia practicemay
contribute to the extent of immunosuppression observed after operation and transfu-
sion [11]. One can speculate that the same variation may apply to various other drugs
or treatment modalities used perioperatively in oncologic patients. Fourth, some
studies simply have an insufficient number ofsubjects to detect even large differences
in outcome between transfused and non-transfused patients. These features, virtually
the antithesis of a randomized controlled investigation, make it all the more remark-
able that any pattern has emerged in studies ofcancer recurrence and transfusion.
Inspiteofthesedifficulties, we believetheweightofevidence supports thecontention
that transfused patients are at significantly greater risk of recurrence than non-
transfused patients in some clinical settings. In our own studies, patients receiving the
larger amounts of plasma and white cell debris in whole blood were at greater risk of
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recurrence than those receiving comparable amounts of red cell concentrates, which
contain lesser amounts of these potentially immunosuppressive substances [12]. Even
though pre-treatment anemia and duration ofsurgery were excellent predictors ofwho
was eventually transfused, these factors were not significant predictors of recurrence
of, or of death due to cancer [13]. Finally, tumor stage and transfusion appear to be
independentand additive predictors ofrecurrenceof, orofdeath duetocancer [14]. At
least in our cohort of patients, the seemingly reasonable contention that transfusion is
acting as a surrogate marker for extent of tumor, difficulty of tumor resection, or
disease severity as measured by anemia, is not supported by a detailed analysis.
Furthermore, of the almost 20 studies performed on colorectal cancer recurrence
and transfusion, those which concluded that transfusion was a significant predictor of
outcome generally involved larger numbers ofpatients (by about 40 percent) than the
negative studies. Thus they were less likely to be afflicted by a type II or beta error.
Moreover, the studies finding a significant association between transfusion and recur-
rence almost invariably included multivariate analysis of other potentially important
predictors of outcome. We suspect that the failure to find a significant association
between transfusion and colorectal cancer recurrence in manyofthenegativestudies is
in large part due to smaller patient numbers, differences in patient selection (e.g.,
omission of patients with certain types of resections or tumors), and choice of
methodologies fordata analysis. Ofnote is the fact thatofalmost 50 studies performed
to date on a variety of tumors, transfusion has yet to be found to be statistically
significantly associated with a favorable influence on tumor recurrence. This result is
surprising given purely stochastic considerations; at least two or three studies might be
expected to have found such a result if transfusion is an irrelevant variable. More
important, some animal data suggest that transfusion might protect against tumor
spread or recurrence; no clinical data exist to support this possibility.
Thehypothesis that stored plasma (i.e., whole blood) and its contents (e.g., whitecell
debris, soluble histocompatibility antigens, immunoglobulins) may be particularly
likely to mediate post-transfusion immunosuppression is supported by results in the
renal transplant setting. Whole blood appears to be a more potent promoter of graft
tolerance than red cells alone [15]. Furthermore, while two recent studies ofthe effect
of whole blood transfusion on cancer recurrence failed to achieve statistical signifi-
cance, in both studies, recipients ofwhole blood did in fact have poorer outcomes than
did recipients ofred cells [16,17]. In one ofthese studies, the authors found that those
transfused patients who had received fresh frozen plasma fared the worst by far [16].
We believe that carefully performed, controlled, randomized studies, with a suffi-
cient number of patients, in which standard blood components are compared with
leukocyte- and plasma-depleted components, are warranted from the current data. We
do not, however, think the data are sufficient to argue for changes in how oncology
patients are currently transfused. There is no evidence that use of washed or frozen-
deglycerolized red cells will materially benefit cancer patients in terms ofthe course of
their disease. On the other hand, pre-operative deposit ofautologous blood for cancer
surgery perhaps deserves more consideration, for a variety of reasons, than has
heretofore been given.
TRANSFUSION AND POST-OPERATIVE INFECTION
Whereas the possible association between transfusion and cancer recurrence re-
mains in considerable doubt, the relationship between perioperative transfusion and
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an increased incidence of bacterial infections appears fairly certain from both animal
and clinical studies. With a few exceptions, animal studies have demonstrated
that transfusion of allogeneic blood, as compared with saline or syngeneic blood,
is associated with greater morbidity or mortality after experimental infection [18].
Furthermore, of 12 clinical studies in which the association between transfusion and
infection could be determined, 11 found thattransfusion wassignificantlyand indepen-
dently associated with an increased risk of bacterial infection [19]. In most of these
studies, even after accounting for factors such as shock, degree of wound contamina-
tion, duration ofsurgery, and type or extent ofinjury or surgery, transfusion remained
a statistically significant predictor of infection. Indeed, in most of these studies,
transfusion was the single most significant predictor ofinfection post-operatively.
In addition to the dramatic association between transfusion and post-operative
infection clinically, there are experimental animal data to demonstrate impaired
monocyte/macrophage function after allogeneic transfusion [20]. Finally, we recently
reported preliminary data that in patients undergoing hip replacement surgery,
patients who received autologous blood only had a much reduced incidence of
post-operative infection compared with a similar group of patients who received
equivalent amounts of homologous blood [21]. Especially convincing is the fact that
the infections in these studies are predominately away from the wound site itself,
suggesting a generalized reduction in host resistance to infection. There are virtually
no data suggesting that transfusion is acting as a surrogate marker or covariate for one
or more other variables that might be expected to predict infection. Even iftransfusion
were acting as a surrogate for suchvariables, one would expect the increase in infection
rate to involve predominately the wound or operative site, which is not the case.
Ifthese data can be extended and confirmed, it appears that post-operative bacterial
infection could be the single most common significant complication associated with
homologous transfusion. Clinical studies have consistently shown a post-operative
infection rate of about 25 to 30 percent in homologously transfused patients, as
compared with a rate of perhaps 5 to 10 percent in non-transfused or autologously
transfused patients in similar clinical settings.
Bacterial infections may not be the only ones potentiated by transfusion. We
reported that patients with post-transfusion AIDS seemed to be disproportionately
those who had received very large amounts ofblood [8]. This finding has recently been
confirmed, suggesting that the severity of post-transfusion immunosuppression after
infection may be a contributing factor in determining which patients develop severe
HIV-1 infection early in their course [22]. Similar preliminary data exist for cytomeg-
alovirus infection [23].
SUMMARY
The bulk of experimental and clinical data support the theory that homologous
transfusion causes down-regulation ofimmunologic functions in many settings. These
changes in immune function may account for the favorable association oftransfusion
with increased renal allograft survival and decreased recurrence in Crohn's disease.
Conversely, these transfusion-induced effects may be causal in the unfavorable associ-
ation with increased cancer recurrence and increased post-transfusion bacterial and
viral infection rates. Host defenses against malignancy and infection may in some
instances be severely compromised by transfusions of homologous blood, but the
circumstances under which this condition occurs remain uncertain. Likewise, the
hypothesis that modification of blood components to contain fewer leukocytes or less
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plasma might ameliorate these effects is attractive, but little or no data exist to support
or refute it.
Perhaps the clearest lesson to be taken from this developing area of research is one
already learned during the 1980s: the safest transfusion is an autologousone, orone not
given, preferably due to a clinical assessment that there is a marginal likelihood of
benefit as compared to the risk.
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